Trimix Intracavernosal Injection Therapy in the Patients with Erectile Dysfunction.
- Author:
Tai Young AHN
1
;
Tae Kyu CHUNG
;
Hyung Keun PARK
;
Keon Seok KIM
;
Myung Su CHOO
Author Information
1. Department of Urology, University of Ulsan, College of Medicine, and Asan Medical Center, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
Impotence;
Intracavernous pharmacotherapy;
Trimix
- MeSH:
Drug Therapy;
Erectile Dysfunction*;
Fibrosis;
Follow-Up Studies;
Granuloma;
Humans;
Male;
Needles;
Papaverine;
Phentolamine
- From:Korean Journal of Urology
1995;36(6):651-657
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
Vasoactive pharmacotherapy is now being widely used as practical and reliable method for the treatment of the patients with erectile dysfunction. But the individual vasoactive agent has limitations in its clinical success and potential for side effects. So, the synergistic effect and low drug volume of each vasoactive drug in polypharmacotherapy of erectile dysfunction have made it possible to reduce both systemic and local complications with excellent success rate. A total of 223 patients with erectile dysfunction underwent a trial of intracavernous self injection therapy with Trimix(the mixture of papaverine, phentolamine and prostaglandin E1). Major underlying diseases were DM(115patients, 51.6%), hypertension(11 patients, 4.9%), spinal injury(three patients, 1.3%) and prior pelvic surgery(three patients, 1.3%). The volume of drug used ranged between 0.04 and 0.6ml(average:0.19ml). After a mean followup of 7.6 months(3-15 months), 141 patients(63.2%) left in the home injection program and among them, 125 patients(88.6%) had very high satisfaction. The drop-out rate was 36.8%(82 of 223) with most of the cases during early home phase. The causes of drop-out were the fear of needle or injection, inadequate response to injection, loss of interest and complications. Priapism(six patients, 3.8%), pain(six patients, 3.8%) and granuloma on injection site(one patient, 0.6%) were noticeable complications, but coporal fibrosis and systemic side effect were not noticed. In conclusion, Trimix intracavernosal injection therapy is minimally invasive, simple, relatively safe and, most of all, very effective method for the treatment of the patients with erectile dysfunctions.
